Dr. Reddy’s Laboratories Limited (NYSE:RDY) to Post FY2027 Earnings of $3.12 Per Share, Zacks Research Forecasts

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Research analysts at Zacks Research decreased their FY2027 earnings estimates for shares of Dr. Reddy’s Laboratories in a research note issued on Wednesday, September 11th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $3.12 for the year, down from their prior forecast of $3.15. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $4.11 per share.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Saturday, July 27th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.10). The company had revenue of $919.80 million for the quarter, compared to the consensus estimate of $861.68 million. Dr. Reddy’s Laboratories had a net margin of 19.28% and a return on equity of 20.32%.

A number of other analysts have also weighed in on the company. Barclays increased their price objective on Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 16th.

Dr. Reddy’s Laboratories Price Performance

RDY opened at $80.25 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.55 and a quick ratio of 1.90. The stock’s 50 day simple moving average is $81.05 and its 200 day simple moving average is $75.61. The firm has a market cap of $13.39 billion, a price-to-earnings ratio of 19.91, a PEG ratio of 1.74 and a beta of 0.55. Dr. Reddy’s Laboratories has a 1 year low of $63.72 and a 1 year high of $84.46.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RDY. QRG Capital Management Inc. raised its holdings in Dr. Reddy’s Laboratories by 45.3% in the 4th quarter. QRG Capital Management Inc. now owns 8,546 shares of the company’s stock worth $595,000 after purchasing an additional 2,664 shares in the last quarter. Baader Bank Aktiengesellschaft raised its stake in Dr. Reddy’s Laboratories by 224.3% in the fourth quarter. Baader Bank Aktiengesellschaft now owns 11,284 shares of the company’s stock worth $785,000 after buying an additional 7,804 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in Dr. Reddy’s Laboratories by 21.0% in the fourth quarter. Quadrant Capital Group LLC now owns 28,420 shares of the company’s stock worth $1,977,000 after buying an additional 4,942 shares during the period. Panagora Asset Management Inc. boosted its position in Dr. Reddy’s Laboratories by 47.5% during the 4th quarter. Panagora Asset Management Inc. now owns 119,794 shares of the company’s stock valued at $8,335,000 after acquiring an additional 38,602 shares in the last quarter. Finally, Balentine LLC boosted its position in Dr. Reddy’s Laboratories by 28.9% during the 4th quarter. Balentine LLC now owns 8,578 shares of the company’s stock valued at $597,000 after acquiring an additional 1,924 shares in the last quarter. Institutional investors own 14.02% of the company’s stock.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.